CARM
Price
$0.21
Change
-$0.01 (-4.55%)
Updated
Apr 25, 02:09 PM (EDT)
Capitalization
8.99M
NGENF
Price
$2.14
Change
+$0.01 (+0.47%)
Updated
Apr 24 closing price
Capitalization
152.23M
Ad is loading...

CARM vs NGENF

Header iconCARM vs NGENF Comparison
Open Charts CARM vs NGENFBanner chart's image
Carisma Therapeutics
Price$0.21
Change-$0.01 (-4.55%)
Volume$410
Capitalization8.99M
NervGen Pharma
Price$2.14
Change+$0.01 (+0.47%)
Volume$51.91K
Capitalization152.23M
CARM vs NGENF Comparison Chart
Loading...
CARM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NGENF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CARM vs. NGENF commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CARM is a StrongBuy and NGENF is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (CARM: $0.22 vs. NGENF: $2.14)
Brand notoriety: CARM and NGENF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CARM: 140% vs. NGENF: 76%
Market capitalization -- CARM: $8.99M vs. NGENF: $152.23M
CARM [@Biotechnology] is valued at $8.99M. NGENF’s [@Biotechnology] market capitalization is $152.23M. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.16B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CARM’s FA Score shows that 0 FA rating(s) are green whileNGENF’s FA Score has 0 green FA rating(s).

  • CARM’s FA Score: 0 green, 5 red.
  • NGENF’s FA Score: 0 green, 5 red.
According to our system of comparison, NGENF is a better buy in the long-term than CARM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CARM’s TA Score shows that 5 TA indicator(s) are bullish while NGENF’s TA Score has 5 bullish TA indicator(s).

  • CARM’s TA Score: 5 bullish, 3 bearish.
  • NGENF’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, CARM is a better buy in the short-term than NGENF.

Price Growth

CARM (@Biotechnology) experienced а +12.08% price change this week, while NGENF (@Biotechnology) price change was -0.56% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.17%. For the same industry, the average monthly price growth was -4.24%, and the average quarterly price growth was -12.55%.

Reported Earning Dates

CARM is expected to report earnings on Mar 31, 2025.

Industries' Descriptions

@Biotechnology (+7.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NGENF($152M) has a higher market cap than CARM($8.99M). NGENF YTD gains are higher at: -1.927 vs. CARM (-48.615). NGENF has higher annual earnings (EBITDA): -27.5M vs. CARM (-63.37M). CARM has more cash in the bank: 26.9M vs. NGENF (21M). NGENF has less debt than CARM: NGENF (129K) vs CARM (3.32M). CARM has higher revenues than NGENF: CARM (20.3M) vs NGENF (0).
CARMNGENFCARM / NGENF
Capitalization8.99M152M6%
EBITDA-63.37M-27.5M230%
Gain YTD-48.615-1.9272,523%
P/E RatioN/AN/A-
Revenue20.3M0-
Total Cash26.9M21M128%
Total Debt3.32M129K2,571%
FUNDAMENTALS RATINGS
CARM vs NGENF: Fundamental Ratings
CARM
NGENF
OUTLOOK RATING
1..100
327
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
91
Overvalued
PROFIT vs RISK RATING
1..100
10042
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
9740
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NGENF's Valuation (91) in the null industry is in the same range as CARM (94). This means that NGENF’s stock grew similarly to CARM’s over the last 12 months.

NGENF's Profit vs Risk Rating (42) in the null industry is somewhat better than the same rating for CARM (100). This means that NGENF’s stock grew somewhat faster than CARM’s over the last 12 months.

NGENF's SMR Rating (98) in the null industry is in the same range as CARM (98). This means that NGENF’s stock grew similarly to CARM’s over the last 12 months.

NGENF's Price Growth Rating (40) in the null industry is somewhat better than the same rating for CARM (97). This means that NGENF’s stock grew somewhat faster than CARM’s over the last 12 months.

NGENF's P/E Growth Rating (100) in the null industry is in the same range as CARM (100). This means that NGENF’s stock grew similarly to CARM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CARMNGENF
RSI
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
80%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 10 days ago
80%
Declines
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Ad is loading...
CARM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NGENF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
POWL184.349.67
+5.54%
Powell Industries
UI312.8511.10
+3.68%
Ubiquiti
ZYXI2.520.08
+3.28%
Zynex
ZVIA2.370.04
+1.72%
Zevia PBC
RY117.67-0.12
-0.10%
Royal Bank of Canada

CARM and

Correlation & Price change

A.I.dvisor indicates that over the last year, CARM has been loosely correlated with TRDA. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if CARM jumps, then TRDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CARM
1D Price
Change %
CARM100%
-1.24%
TRDA - CARM
39%
Loosely correlated
+2.87%
ERAS - CARM
39%
Loosely correlated
-1.41%
ADCT - CARM
35%
Loosely correlated
+5.43%
CGON - CARM
34%
Loosely correlated
+3.81%
BEAM - CARM
34%
Loosely correlated
+1.51%
More

NGENF and

Correlation & Price change

A.I.dvisor tells us that NGENF and CYTK have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NGENF and CYTK's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NGENF
1D Price
Change %
NGENF100%
+0.38%
CYTK - NGENF
25%
Poorly correlated
+6.13%
IBRX - NGENF
23%
Poorly correlated
N/A
TNFA - NGENF
22%
Poorly correlated
+2.07%
CARM - NGENF
22%
Poorly correlated
-1.24%
ATRA - NGENF
22%
Poorly correlated
+10.14%
More